NCT03746652View on ClinicalTrials.gov

Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

PHASE2UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Multiple Myeloma
Interventions
DRUG

Daratumumab, Ixazomib, Dexamethasone

Daratumumab 16 mg/kg, Ixazomib 4 mg, Dexamethasone 40 mg

Trial Locations (1)

11528

"General Hospital of Athens Alexandra", Athens

Sponsors
All Listed Sponsors
collaborator

Janssen Pharmaceutica NV

UNKNOWN

collaborator

Takeda

INDUSTRY

lead

Hellenic Society of Hematology

OTHER

NCT03746652 - Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter